Spatial Multi-Omics Identifies Early Synaptic Pruning and Context-Specific Dopaminergic Vulnerability in Synucleinopathies
Objective: To investigate the significance of Lewy body pathology (LBP) in relation to midbrain molecular and cellular changes associated with Parkinson's disease (PD). Background: The…Ventral and Dorsal Language Pathways in Patients with Lewy Bodies: an fMRI Study of Syntactic Sentence Processing
Objective: Aim of this study is to describe specific alterations in comprehending syntactically complex sentences in patients with Lewy body diseases (LBDs) that already have…Identifying Cut-off Values, Effects of AD Co-pathology, Sex Differences, and Temporal Changes of 123I-FP-CIT SPECT in Autopsy-proven LBD
Objective: We analyzed autopsy-proven Lewy body disease (LBD) and/or Alzheimer’s disease (AD) dementia patients with 123I-FP-CIT SPECT to investigate previously unclarified detailed aspects of 123I-FP-CIT…Seed amplification assay detects alpha-synuclein in cerebrospinal fluid in pre- and symptomatic autosomal dominant Alzheimer’s disease
Objective: To examine the ability to detect concurrent Lewy Body Disease via Lew Body pathology (LBP) in Autosomal Dominant Alzheimer’s Disease (ADAD) through detection of…Efficacy of Stimulant Use for Cognitive Fluctuations in Lewy Body Dementia: A Case Study
Objective: To evaluate the effectiveness of stimulants in reducing cognitive fluctuations in Lewy Body Dementia (LBD). Background: Lewy Body Dementia (LBD) is the 2nd most…Sex differences in regional densities of Lewy body pathology
Objective: To assess sex differences in regional Lewy body pathology densities and their clinical correlations in cases with Lewy body (LB) pathology at autopsy. Background:…Lewy Pathology in the Peripheral Nervous System of SNCA Duplication
Objective: This study aimed to investigate the degree, distribution, and biochemical profile of phosphorylated α-synuclein (p-α-syn) in the peripheral nervous system of patients with SNCA…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body
Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia
Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
- 1
- 2
- 3
- …
- 10
- Next Page »